Objective To observe the characteristics of magnetic resonance diffusion tensor imaging（MR-DTI）for optic nerves and optic radiation in blind patients.Methods The optic nerves and optic radiation of 20 blind patients（blind group）and 20 controls（control group） were scanned by MR-DTI. Fractional anisotropy (FA) and directional encoded color (DEC) maps were acquired through postprocessing with the aid of volumeone 1.72 software. The signal intensity of optic nerves and optic radiation were then observed. The FA, mean diffusivity (MD), lambda;∥ and lambda;perp; value of bilateral optic nerves and optic radiation in two groups were measured in the DEC maps.Results While the high signal intensity was found in bilateral optic nerves in FA and DEC maps in control group，the signal decreased markedly in the blind group. The FA and lambda;∥ value of optic nerves in the blind group were declined obviously compared to that in the control group. The difference was statistically significant (t=16.294, 14.660;P=0.000). The MD and lambda;perp; value of optic nerves in the blind group were increased obviously compared to that in the control group, the difference was also statistically significant (t=8.096, 8.538; P=0.000). The high signal intensity was found in bilateral optic radiation in FA and DEC maps in both the blind and control groups. There were no statistic differences in FA and MD value in bilateral optic radiation between the blind and control groups (Left：t=1.456，1.811；P=0.152，0.076. Right：t=0.779，0.073；P=0.440，0.942). Conclusion A low signal intensity of bilateral optic nerves and a high signal intensity of bilateral optic radiation were found in blind patients.
Objective lt;brgt;To study the clinical results and safty of photodynamic therapy (PDT) after single and multi-treatments of patients with subfoveal choroidal neovascularization (CNV) caused by wet agerelated macular degeneration (AMD). lt;brgt; lt;brgt;Methods lt;brgt;From July, 2000 to July, 2001, 20 wet AMD patients (31 eyes) 4788 years old (mean 68.2 years old) with best-corrected visual acuity from FC/10 cm to 0.6 diagnosed through optic coherence tomography (OCT), fluorescein angiography (FFA) and indocyanine green angiography (ICGA) were treated with PDT. All cases were assigned to benzoporphyrin derivative mono acid (BPD) (6 mg per square meter of body surface area), administered via intravenous infusion of 30 ml over 10 minutes. Fifteen minutes after the start of the infusion, a laser light at 689 nm (Zeiss company, German) delivered 50 J/cm2 at an intensity of 600 mW/cm2 over 83 seconds on CNV. Visual acuity, photochrome of ocular fundus, OCT, FFA, ICGA were used to evaluate the effects of photodynamic therapy with BPD. Follow-up of these patients was planned 1-2 week and every 3 month after PDT. Once the lesion area progressed, PDT was applied again. Tweenty cases (31 eyes) were followed up from 3 to 18 months (average 12 month).In 1 affected eye, PDT was applied fow 4 times, 4 eye for 2 times, and the other 26 eyes for 1 time. lt;brgt;Results lt;brgt;The visual acuity in 13 (41.9%) eyes was improved (increase≥2 lines) after PDT. Stabilized (±1 line) in 17 (54.8%) eyes and decreased 2 lines（attributed to the recur of CNV ）in 1 (3.2%) eye. After PDT, the fundus haemorrhage and fluid leakage reduced. FFA and ICGA showed. cessation and obvious reduction of fluorescein leakage from CNV in all patients 2 weeks after photodynamic therapy, and retreatment decreased the leakage step by step. Fluorescein leakage from at least a portion of the CNV reappeared by 1-3 month after treatment in some cases. OCT also showed the reduction of the size of CNV, moreover, the edema of surrounding retina and choriodal and serous neural epithelial detachment recovered obviously. No side affect during and after PDT was noticed. lt;brgt;Conclusions lt;brgt;PDT with BPD can achieve short-term effect on part or total cessation of fluorescein leakage from CNV without loss of vision or growth of classic CNV in patients with age-related macular degeneration, retreatment of PDT was also effective. lt;brgt; lt;brgt;(Chin J Ocul Fundus Dis, 2002, 18: 175-179)
One of the key problems of brain-computer interfaces (BCI) is low signal-to-noise ratio (SNR) of electroencephalogram (EEG) signals. It affects recognition performance. To remove the artifact and noise, block under-determined blind source separation method based on the small number of channels is proposed in this paper. The non-stationary EEG signals are turned into block stationary signals by piecewise. The mixing matrix is estimated by the second-order under-determined blind mixing matrix identification. Then, the beamformer based on minimum mean square error separates the original sources of signals. Eventually, the reconstructed EEG for mixed signals removes the unwanted components of source signals to achieve suppressing artifact. The experiment results on the real motor imagery BCI indicated that the block under-determined blind source separation method could reconstruct signals and remove artifact effectively. The accuracy of motor imagery task of BCI has been greatly improved.
【摘要】 目的 探讨小儿白血病合并回盲肠综合征的临床特点、诊断及治疗。方法 对2005年2月—2009年10月间4例小儿白血病合并回盲肠综合征的临床症状、体征及辅助检查进行回顾性分析。结果 在小儿白血病的治疗过程中,可出现回盲肠综合征。临床表现为腹痛、腹胀及腹泻等;查体可见腹肌紧张,右下腹压痛,或有反跳痛等;血常规中白细胞减少,尤其中性粒白细胞显著下降;给予抗感染,静脉营养,丙种球蛋白增强机体抵抗力,输浓缩红细胞及血小板支持治疗,可以收到较好的治疗效果。若保守治疗症状得不到缓解,或病情加重,可行手术治疗。结论 回盲肠综合征是小儿白血病治疗过程的合并症,其临床表现复杂,体征缺乏特异性,根据不同的病情采用相应的治疗方法可收到良好的临床效果。
Objective To assess the effectiveness and safety of prulifloxacin in the treatment of urinary tract infection. Methods The double-blind, double dummy and randomized controlled method was adopted. One hundred and forty-four patients were randomized to the treatment group (prulifloxacin , 4 tablets, bid) and the control group (levofloxacin, 4 tablets, bid). The randomization code was produced by computer. The treatment duration for both groups was from 7 to 10 days. Results Data were analyzed on the basis of full analysis sets (FAS) and per-protocol (PP) analysis. The total improvement rates of the trial and control groups were 85.07% and 88.52% respectively by FAS analysis, and 90.48% and 91.53% respectively by PP analysis. There was no significant difference between the two groups in improvement rates (Pgt;0.05). Bacterial negative rates in the trial and control groups were 93.75% and 93.88% respectively by FAS analysis and 97.83% and 97.87% respectively by PP analysis. The results showed no statistical significance difference between the two groups in bacterial negative rates (Pgt;0.05). The adverse events in the prulifloxacin and levofloxacin groups were 2.80% and 5.60% respectively. Conclusion Prulifloxacin has the same clinical effectiveness as levofloxacin with a few toxic adverse effects in the treatment of urinary tract infection.
Objective To assess the effectiveness and safety of tinidazole buccal tablets produced by China Associate Pharmaceutical Co. , Ltd. on periodontitis and pericoronitis. Methods A mukicenter randomized controlled doubleblind trial was designed. Three units from Shanghai, Hangzhou and Chengdu joined the study. The trial tablet oftinidazole was supplied by the mentioned Pharmaceuticals company. A marketed tinidazole produced by Zhejiang Hacon Marine BioPharmaceutical Co. Ltd. , was used as positive control. Both drugs were administered at a dose of 5 mg four times daily for 6 days. Outcomes measurement included symptoms, clinical signs of the patients with periodontitis or pericoronitis, and gingival index （GI）, bleeding index （BI）, plaque index （PI） and periodontal depth （PD） were measured for the patients with periodontitis. Subgingival bacterial samples taken from subgingival plaque of diseased teeth of the cases with periodontitis or from exudates of diseased wisdom teeth of the cases with pericoronitis were cultivated aerobically and anaerobically. Putative microorganisms were isolated and colony forming unit （CFU） were counted before and after treatments. All adverse drug reactions （ADIL） were observed, recorded, properly treated and followed. Results Altogether, 157 cases met the inclusion criteria and entered the study. Lost to follow-up happened in 14 cases with drop-out rate of 8.9%. In per-protocal cases there were 109 with periodontitis （57 in trial group and 52 in control group） and 34 with pericoronitis （17 in trial group and 17 in control group）. Basehne analysis demonstrated that the two groups were comparable. At the final examination, it was found that 85% of the cases in the periodontitis group showed significant）mprovement gingival bleeding, both gingival pain and biting pain subsided, PD, BI, GI and PI reduced with no significant difference between trial and control groups （P 〉0.05）. The symptoms of sixty percent of cases with pericoronitis were improved. More than 75% of the cases with pericoronal pus, the pus were ehminated. Over 60% of the cases with lymphadenitis, the node swelling was subsided. Mouth opening increased in all cases with pericoronitis. All improvements in the cases with pericoronitis showed no significant difference between trial and control groups （ P 〉0.05 ）. The effective rate only including cured and markedly improved cases reached 88.2% in both groups of pericoronitis. Various species of putative microorganisms were detected in patients with periodontitis or pericoronitis before treatment. A great proportion of the putative microorganisms eliminated or the quantity reduced after treatment, with no significant difference between trial and control groups （P 〉0.05 ）. Candida albicans was not detected before and after treatment. Nine patients developed ADRs, 5 （6.8% ）in trial group and 4 （5.8% ）in control group. All the ADRs were mild and transient, not interfering with drug administration. Conclusions This study showed the tinidozole buccal tablet with commercial name “Jinhe” supphed by China Associate Pharmaceutical Co. , Ltd. do inhibit the common putative microorganisms of periodontitis and pericoronitits, and do not influence balance of the local commensal microganisms. It reduces severity of the infectious inflammation and benefits improvement and/ or rehabilitation of periodontitis and pericoronitis, with only mild and transient ADRs. The trial and control tablets have similar efficacy and safety for patients with periodontits or pericoronitis.